26 February 2020 - Rhonda Lumsden was suffering from stage 4 lung cancer and out of options, when a new drug gave her a second chance.

Now that same chance has been extended to thousands of other patients in a similar situation, after the federal government added it to the Pharmaceutical Benefits Scheme.

The drug, durvalumab, which is sold commercially as Imfinzi, is an immunotherapy that specifically targets non-small-cell lung cancer.

Read Brisbane Times article